-
Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases
| 14 February 2008 |
Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).
-
Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee
| 23 May 2007 |
At its meeting on 12 December 2006, the Reimbursement Committee resumed the reassessment of the reimbursement status of blood pressure products.
-
New reimbursement status of lipid lowering medicinal products enters into force on 23 April 2007
| 29 March 2007 |
As of 23 April 2007, the reimbursement status of lipid lowering medicinal products will be changed. The decision includes all lipid lowering medicinal products with marketing authorisations in Denmark on 15 March 2007.
-
Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10
| 15 February 2007 |
In connection with the reassessment of the reimbursement status of medicinal products, the Reimbursement Committee discussed the reimbursement status of certain ATC groups at its meeting on 16 January 2007.
-
Reassessment of reimbursement status for medicinal products for hypertension
| 18 December 2006 |
In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.
-
Reassessment of reimbursement status of the remaining subgroups of ATC group C
| 18 December 2006 |
The Danish Medicines Agency previously notified companies and a number of scientific societies and patient organisations about which ATC groups and subgroups would be the first to be reassessed, cf. the fact box to the right.
-
Reassessment of ATC-groups C01, C04 and C05
| 18 December 2006 |
At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.
-
Reassessment of reimbursement status of ATC-groups C01, C04 and C05
| 18 December 2006 |
At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.
-
Reassessment of reimbursement status
| 18 December 2006 |
This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.
-
Reimbursement status of medicinal products aginst hypertension
| 18 December 2006 |
On 6 March 2006, the Danish Medicines Agency wrote a letter to a number of scientific societies to make them clarify certain aspects of the treatment of hypertension in Denmark.
-
Reassessment of ATC group A, Alimentary tract and metabolism
| 18 December 2006 |
At the beginning of 2007, the Danish Medicines Agency is going to begin the reassessment of ATC group A, alimentary tract and metabolism, starting with.
-
Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products
| 18 December 2006 |
At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.
-
Reassessment of subgroups in ATC group C
| 24 April 2006 |
The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.
-
Letter to scientific societies on treatment of hypertension
| 24 April 2006 |
As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.
-
Bevilling til Brædstrup Apotek
Lægemiddelstyrelsen har den 12. september 2018 meddelt Kerly Maire Servilieri bevilling til at drive Brædstrup Apotek.
-
Danish Medicines Agency shortens the review time for applications for COVID-19 medicine trials
Drug regulatory authorities around the world are taking several steps to speed up the development and availability of medicines to treat and prevent novel COVID-19. The Danish Medicines Agency in Denmark has just implemented an emergency procedure for applications for clinical trials with human subjects.
-
EMA: No evidence linking ibuprofen to worsening of COVID-19
The press and social media have raised questions about whether ibuprofen could worsen the condition of patients infected with COVID-19. The European Medicines Agency reports that there is currently no scientific evidence to suggest this. The Data Analytics Center of the Danish Medicines Agency now launches an ultra-quick study.
-
Henstilling om, hvordan præparatet remdesivir skal bruges til behandling af COVID-19 i såkaldt compassionate use-programs i EU
Under et ekstraordinært møde, der blev afholdt den 2. april 2020, gav det europæiske medicinalagentur EMA's humane lægemiddeludvalg (CHMP) henstillinger om, hvordan præparatet remdesivir skal bruges til behandling af COVID-19 i såkaldt compassionate use-programs i EU, dvs. via udleveringstilladelser.
-
COVID-19: Restriction on OTC medicines lifted
The Danish Medicines Agency lifts the restriction on over-the-counter (OTC), which has been in force since March. This means that pharmacies, supermarkets, kiosks and others with permission to sell OTC medicines can resume selling more than one pack of the same type of OTC medicine per customer.
